The upcoming three years are crucial and UCB Mexico wants to play a role elevating the standard of care in our country
In Conversation
Oncolytic virus is not necessarily a competitor of standard therapies that are already present in the market such as CAR-T or checkpoint inhibitors. Oncolytic virus works…
High scientific quality is also really important to us, as well as transparency in our reporting. This way, we aim to contribute to sustainable, accessible and…
The core business – our research-driven, data-driven approach to innovation – has not changed [post-IPO]. We are committed to developing our portfolio and generating value for…
We want to see the emergence of an ecosystem of clinical research and position Morocco as an expert hub like other countries such as Tunisia, Egypt…
In order to achieve sustained double-digit growth, we need to invest in training, education, awareness and work hand in hand with physicians to identify the right…
From early research and development, through manufacturing and drug delivery to the patient, our employees in Belgium make a significant contribution to the health of patients…
The US is the largest generics market in the world, so it is an absolutely key market for Sandoz, representing around 26 percent of our global…
The silver lining of the crisis is that it has provided opportunities for small companies to work together and perhaps grow together
We need to have everyone on board, in order to improve the quality of cancer care in Belgium, attract more clinical trials and be able to…
Today, we are independent and self-reliant since we can register our in-house products and out-license them to other pharma companies for additional marketing authorizations
There seems to be a mutual understanding among stakeholders that if we work in silos it will be impossible to face the challenges that the future…
